Protagonist Therapeutics price target raised to $76 from $60 at Truist
Truist raised the firm’s price target on Protagonist Therapeutics (PTGX) to $76 from $60 and keeps a Buy rating on the shares. The firm cites ...
Equity Residential price target raised to $78 from $76 at Truist
Truist raised the firm’s price target on Equity Residential (EQR) to $78 from $76 and keeps a Buy rating on the shares. The firm updated ...